echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The enterprise's centralized procurement quotes "do not emphasize military ethics", how do manufacturers make choices?

    The enterprise's centralized procurement quotes "do not emphasize military ethics", how do manufacturers make choices?

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    49 ,、,。
     
    ,,。,,。
     
    A,。,。(),,。
     
    ,,B,“”。“”,,。。
     
    “”
     
    “”。,、,,。
     
    How is the implementation? The second batch of national procurement has been implemented for one year, showing the following characteristics, but it is also expected: the sales volume will decline slightly, and the sales volume will plummet.
    The slight decrease in sales volume was due to volume purchases, which must be completed.
    Sales plummeted because the price plunged.
    For example, Amoxicillin's sales plummeted from 30 million yuan in a single quarter to several million yuan.
    In short, in terms of hospital sales and value, companies that originally won the bid with high prices have basically withdrawn from the public hospital market.
     
    Did the new so-called "spoilers" take advantage of it? Not necessarily, sales and prices are right there.
    The spoilers seem to "do not speak martial ethics", but in fact there is a lot of mystery behind them.
    After the second batch of national procurement, foreign-funded enterprises gradually withdrew from centralized procurement at all levels.
    Of course, they have their own considerations, such as the global market, such as brand influence, such as the participation of innovative drugs in national talks.
    Probably, under the current centralized procurement rules, there is something to do or not to do.
     
      On the other hand, domestic companies have finally had the opportunity to enter public hospitals, and naturally they have to seize the opportunity at all costs.
    The domestic industrial enterprises that participated in the centralized procurement and ultimately won, mainly include the following two categories:
     
      The first category is large-scale enterprises with super comprehensive strength.
    On research and development, a lot of new products are lining up.
    In terms of scale, a single factory with a large production capacity can guarantee national supply.
    In terms of cost control, if the production capacity goes up, the cost will naturally come down.
    On the extension of upstream and downstream industries, there are raw material and packaging material production companies in the upstream, and pharmaceutical companies and marketing teams in the downstream .
    When collecting quotations, the prices can naturally be explored to the end.
     
      Another type of enterprise has been in the circulation market for many years and does not involve the public hospital market.
    This type of company has been in the market for many years and has long been accustomed to price fighting, and cost control is its trick.
    The author has worked for many years in a company with circulation and pharmnet.
    com.
    cn/" target="_blank">investment promotion as its main sales model, and has seen many varieties that cost about 1 yuan per bottle (100 tablets).
    It is not that the quality of these products is unqualified, but that the cost control is done well.
    Large-scale purchase of raw materials, continuous batch feeding, piece-rate wages for workers, large-size inner and outer packaging.
    .
    .
    In short, within the scope of laws and regulations, the cost control is achieved to the extreme.
     
      Which province does not have a large number of such industrial enterprises.
    In addition, they are also selecting varieties with sales advantages, actively making consistency evaluations, and participating in national procurement.
    Even if there is no R&D capability and the consistency evaluation is hindered, you can still participate in the provincial centralized procurement.
    This time, the collection of more than 30 varieties in Henan attracted nearly 300 manufacturers to participate, with the highest drop of 98%.
     
      Is the low-price bidding chicken ribs?
     
      Under the new normal of centralized procurement, instead of complaining about others, people in the industry should calm down and consider how to deal with it, because this is just the beginning.
     
      Centralized procurement has the advantages of centralized procurement.
    In the face of price competition, some companies withdraw from "group chat.
    " They have no way or can't find a better solution in a short time.
    It can be seen how important it is to take precautions and how helpless it is to boil frogs in warm water.
    Especially companies that rely on a few clinical varieties to dominate the world, because they have good sales and profits every year, the sense of crisis is not strong, and they are accustomed to lying down and winning, which leads to the deterioration of their limbs.
    Once centralized procurement came, the public hospital market that depended on for survival disappeared at once.
     
      Collect prices, there is no cost advantage.
    I quoted 1.
    2 yuan, but I couldn't produce it at 2.
    1 yuan, so I would pay for how much I produced.
    Let's fight for research and development.
    I haven't done it for so many years, and no new products will be released in the future.
    This is difficult to handle, and it is difficult for a clever woman to cook without rice.
    It may be a good choice to adjust sales channels, focus on controlled sales or commercial markets, and transform sales models.
    It's not too late to make up for it.
     
      Whether or not winning the bid at a low price for centralized procurement is a tasteless one depends on the strength of the enterprise and the pattern of the marketing trader.
    A certain manufacturer's indapamide tablets won the bid for centralized procurement in a large province in central China.
    The research organization concluded that the clinical market sales of indapamide tablets are small, and the volume and price have not changed much, but some product traders use the opportunity of provincial procurement to develop a series of market planning and marketing plans.
    There has been little change, but the sales volume of the province has increased by leaps and bounds from dozens of pieces in January to 3,000 pieces in a month.
    The market share has soared and the province's commercial sales network has been systematically established.
    This is called a borrowing.
     
      For the significance of centralized procurement, we cannot just look at the sales and profits of hospitals.
    Hospital clinical sales are the engine of pharmaceutical market sales.
    To seize the clinical market is equivalent to seizing the commanding heights of marketing.
    On the contrary, if you lose the hospital market, you may be able to survive a period of time due to medication compliance in a short period of time.
    In the long run, it is inevitable that market share will decrease, unless you want to voluntarily give up.
     
      Therefore, centralized harvesting is not chicken ribs, but very important.
    The key is to choose a high place and go to a wide place.
     
      Sales transformation to other channels
     
      What should the manufacturer do? The author offers three suggestions:
     
      1.
    Actively do consistency evaluation and participate in the national centralized procurement and provincial-level Group A competition.
    Although it is impossible to predict which varieties will be included in the collection at all levels, it is always good to take precautions.
    Forewarned is forearmed, without prejudging the waste.
     
      2.
    Control product costs and be prepared for price competition.
    Cost control is a manifestation of the comprehensive strength of industrial enterprises, involving all aspects of business operations, including production capacity, management, supply chain, marketing, equipment, technology, scale, and so on.
    The cost is well controlled.
    The high price of the winning election can increase profits, and the low price of the winning election can be invincible.
     
      3.
    Sales transformation, there is no way to go.
    An pharmnet.
    com.
    cn/agent_product/" target="_blank">agent tells the author, after Jicai, his loss of a variety of hospital sales of 1 million boxes a year in the province.
    However, the problem is not big, he has more varieties, not bright in the east and bright in the west.
    The same is true for the industry.
    Although the selection of varieties is not as flexible as the agents, the ship is easy to turn around, and the sales transformation can be done in time.
    Starting from other channels and terminals, the room for maneuver is not small.
     
      After all, manufacturers are "bookmakers" with varieties in their hands, and when agents face the huge competition for centralized procurement by the Medical Insurance Bureau, they have to withstand the adjustment of medical insurance catalogues, the increase in operating costs such as rent and labor, and the "two-invoice system" is combined.
    A series of severe tests such as increased regulatory risks, flat channels, and e-commerce impacts have not been small.
     
      For agents to break through, they must first make correct predictions on centralized procurement policies and varieties.
    Centralized procurement must be normalized, and biosimilar drugs and proprietary Chinese medicines will also be included.
    Agents must be predictable when choosing varieties: Don’t act as agents for the varieties that are about to be collected.
    Otherwise, after two or three years, the market will be hard to cultivate.
    When they encounter centralized sourcing, the manufacturer will withdraw the agency right.
    When looking for new drugs with clinical value, or varieties that have not been included in the scope of national centralized procurement.
    At the channel level, it is possible to expand out-of-hospital channels while retaining the advantages of clinical channels.
    After all, centralized procurement is mainly aimed at stock varieties and the hospital market, while the pharmaceutical industry has three major channels and six major terminals.
      According to the medical network on April 9th, National Procurement has reached the fourth batch.
    Whether it is national centralized procurement, provincial centralized procurement, or alliance centralized procurement, centralized drug procurement has become the new normal for public medical institutions.
     
      The Medical Insurance Bureau directly faces the manufacturers.
    In terms of centralized procurement, all manufacturers stand on the same starting line.
    The author combed through the rules of centralized procurement and found that national centralized procurement and provincial centralized procurement can be divided into two levels.
    The main criterion is whether it has passed the consistency evaluation.
     
      National centralized procurement and provincial centralized procurement A group classification, mainly the original research manufacturers and over-evaluated manufacturers to participate in the competition.
    Varieties passed the consistency evaluation and obtained the priority right to connect to the Internet by public medical institutions.
    More than three varieties (including the original research) have passed the consistency evaluation and are automatically included in the biannual national procurement catalog to obtain the qualification to compete for national public hospitals.
     
      Varieties have not passed the consistency evaluation and can participate in provincial harvesting, but they are grouped in group B, which can also be said to be the "death group".
    Because the provincial procurement level adopts the "double envelope" rule, it only looks at the economic standard and fights the price.
    The price has become the decisive factor for the selection of centralized procurement at all levels.
     
       The "spoiler" has a mystery
     
      Some companies offer "do not emphasize military ethics.
    " In particular, the generic medicines with many manufacturers , whether it is Amoxicillin, Indapamide, or Omeprazole from the province, all have won the bid at an ultra-low price for a few cents.
     
      How is the implementation? The second batch of national procurement has been implemented for one year, showing the following characteristics, but it is also expected: the sales volume will decline slightly, and the sales volume will plummet.
    The slight decrease in sales volume was due to volume purchases, which must be completed.
    Sales plummeted because the price plunged.
    For example, Amoxicillin's sales plummeted from 30 million yuan in a single quarter to several million yuan.
    In short, in terms of hospital sales and value, companies that originally won the bid with high prices have basically withdrawn from the public hospital market.
     
      Did the new so-called "spoilers" take advantage of it? Not necessarily, sales and prices are right there.
    The spoilers seem to "do not speak martial ethics", but in fact there is a lot of mystery behind them.
    After the second batch of national procurement, foreign-funded enterprises gradually withdrew from centralized procurement at all levels.
    Of course, they have their own considerations, such as the global market, such as brand influence, such as the participation of innovative drugs in national talks.
    Probably, under the current centralized procurement rules, there is something to do or not to do.
     
      On the other hand, domestic companies have finally had the opportunity to enter public hospitals, and naturally they have to seize the opportunity at all costs.
    The domestic industrial enterprises that participated in the centralized procurement and ultimately won, mainly include the following two categories:
     
      The first category is large-scale enterprises with super comprehensive strength.
    On research and development, a lot of new products are lining up.
    In terms of scale, a single factory with a large production capacity can guarantee national supply.
    In terms of cost control, if the production capacity goes up, the cost will naturally come down.
    On the extension of upstream and downstream industries, there are raw material and packaging material production companies in the upstream, and pharmaceutical companies and marketing teams in the downstream .
    When collecting quotations, the prices can naturally be explored to the end.
     
      Another type of enterprise has been in the circulation market for many years and does not involve the public hospital market.
    This type of company has been in the market for many years and has long been accustomed to price fighting, and cost control is its trick.
    The author has worked for many years in a company with circulation and pharmnet.
    com.
    cn/" target="_blank">investment promotion as its main sales model, and has seen many varieties that cost about 1 yuan per bottle (100 tablets).
    It is not that the quality of these products is unqualified, but that the cost control is done well.
    Large-scale purchase of raw materials, continuous batch feeding, piece-rate wages for workers, large-size inner and outer packaging.
    .
    .
    In short, within the scope of laws and regulations, the cost control is achieved to the extreme.
     
      Which province does not have a large number of such industrial enterprises.
    In addition, they are also selecting varieties with sales advantages, actively making consistency evaluations, and participating in national procurement.
    Even if there is no R&D capability and the consistency evaluation is hindered, you can still participate in the provincial centralized procurement.
    This time, the collection of more than 30 varieties in Henan attracted nearly 300 manufacturers to participate, with the highest drop of 98%.
     
      Is the low-price bidding chicken ribs?
     
      Under the new normal of centralized procurement, instead of complaining about others, people in the industry should calm down and consider how to deal with it, because this is just the beginning.
     
      Centralized procurement has the advantages of centralized procurement.
    In the face of price competition, some companies withdraw from "group chat.
    " They have no way or can't find a better solution in a short time.
    It can be seen how important it is to take precautions and how helpless it is to boil frogs in warm water.
    Especially companies that rely on a few clinical varieties to dominate the world, because they have good sales and profits every year, the sense of crisis is not strong, and they are accustomed to lying down and winning, which leads to the deterioration of their limbs.
    Once centralized procurement came, the public hospital market that depended on for survival disappeared at once.
     
      Collect prices, there is no cost advantage.
    I quoted 1.
    2 yuan, but I couldn't produce it at 2.
    1 yuan, so I would pay for how much I produced.
    Let's fight for research and development.
    I haven't done it for so many years, and no new products will be released in the future.
    This is difficult to handle, and it is difficult for a clever woman to cook without rice.
    It may be a good choice to adjust sales channels, focus on controlled sales or commercial markets, and transform sales models.
    It's not too late to make up for it.
     
      Whether or not winning the bid at a low price for centralized procurement is a tasteless one depends on the strength of the enterprise and the pattern of the marketing trader.
    A certain manufacturer's indapamide tablets won the bid for centralized procurement in a large province in central China.
    The research organization concluded that the clinical market sales of indapamide tablets are small, and the volume and price have not changed much, but some product traders use the opportunity of provincial procurement to develop a series of market planning and marketing plans.
    There has been little change, but the sales volume of the province has increased by leaps and bounds from dozens of pieces in January to 3,000 pieces in a month.
    The market share has soared and the province's commercial sales network has been systematically established.
    This is called a borrowing.
     
      For the significance of centralized procurement, we cannot just look at the sales and profits of hospitals.
    Hospital clinical sales are the engine of pharmaceutical market sales.
    To seize the clinical market is equivalent to seizing the commanding heights of marketing.
    On the contrary, if you lose the hospital market, you may be able to survive a period of time due to medication compliance in a short period of time.
    In the long run, it is inevitable that market share will decrease, unless you want to voluntarily give up.
     
      Therefore, centralized harvesting is not chicken ribs, but very important.
    The key is to choose a high place and go to a wide place.
     
      Sales transformation to other channels
     
      What should the manufacturer do? The author offers three suggestions:
     
      1.
    Actively do consistency evaluation and participate in the national centralized procurement and provincial-level Group A competition.
    Although it is impossible to predict which varieties will be included in the collection at all levels, it is always good to take precautions.
    Forewarned is forearmed, without prejudging the waste.
     
      2.
    Control product costs and be prepared for price competition.
    Cost control is a manifestation of the comprehensive strength of industrial enterprises, involving all aspects of business operations, including production capacity, management, supply chain, marketing, equipment, technology, scale, and so on.
    The cost is well controlled.
    The high price of the winning election can increase profits, and the low price of the winning election can be invincible.
     
      3.
    Sales transformation, there is no way to go.
    An pharmnet.
    com.
    cn/agent_product/" target="_blank">agent tells the author, after Jicai, his loss of a variety of hospital sales of 1 million boxes a year in the province.
    However, the problem is not big, he has more varieties, not bright in the east and bright in the west.
    The same is true for the industry.
    Although the selection of varieties is not as flexible as the agents, the ship is easy to turn around, and the sales transformation can be done in time.
    Starting from other channels and terminals, the room for maneuver is not small.
     
      After all, manufacturers are "bookmakers" with varieties in their hands, and when agents face the huge competition for centralized procurement by the Medical Insurance Bureau, they have to withstand the adjustment of medical insurance catalogues, the increase in operating costs such as rent and labor, and the "two-invoice system" is combined.
    A series of severe tests such as increased regulatory risks, flat channels, and e-commerce impacts have not been small.
     
      For agents to break through, they must first make correct predictions on centralized procurement policies and varieties.
    Centralized procurement must be normalized, and biosimilar drugs and proprietary Chinese medicines will also be included.
    Agents must be predictable when choosing varieties: Don’t act as agents for the varieties that are about to be collected.
    Otherwise, after two or three years, the market will be hard to cultivate.
    When they encounter centralized sourcing, the manufacturer will withdraw the agency right.
    When looking for new drugs with clinical value, or varieties that have not been included in the scope of national centralized procurement.
    At the channel level, it is possible to expand out-of-hospital channels while retaining the advantages of clinical channels.
    After all, centralized procurement is mainly aimed at stock varieties and the hospital market, while the pharmaceutical industry has three major channels and six major terminals.
      According to the medical network on April 9th, National Procurement has reached the fourth batch.
    Whether it is national centralized procurement, provincial centralized procurement, or alliance centralized procurement, centralized drug procurement has become the new normal for public medical institutions.
     
      The Medical Insurance Bureau directly faces the manufacturers.
    In terms of centralized procurement, all manufacturers stand on the same starting line.
    The author combed through the rules of centralized procurement and found that national centralized procurement and provincial centralized procurement can be divided into two levels.
    The main criterion is whether it has passed the consistency evaluation.
     
      National centralized procurement and provincial centralized procurement A group classification, mainly the original research manufacturers and over-evaluated manufacturers to participate in the competition.
    Varieties passed the consistency evaluation and obtained the priority right to connect to the Internet by public medical institutions.
    More than three varieties (including the original research) have passed the consistency evaluation and are automatically included in the biannual national procurement catalog to obtain the qualification to compete for national public hospitals.
     
      Varieties have not passed the consistency evaluation and can participate in provincial harvesting, but they are grouped in group B, which can also be said to be the "death group".
    Because the provincial procurement level adopts the "double envelope" rule, it only looks at the economic standard and fights the price.
    The price has become the decisive factor for the selection of centralized procurement at all levels.
     
       The "spoiler" has a mystery
       The "spoiler" has a mystery
     
      Some companies offer "do not emphasize military ethics.
    " In particular, the generic medicines with many manufacturers , whether it is Amoxicillin, Indapamide, or Omeprazole from the province, all have won the bid at an ultra-low price for a few cents.
    Enterprise enterprise enterprise medicine medicine medicine
     
      How is the implementation? The second batch of national procurement has been implemented for one year, showing the following characteristics, but it is also expected: the sales volume will decline slightly, and the sales volume will plummet.
    The slight decrease in sales volume was due to volume purchases, which must be completed.
    Sales plummeted because the price plunged.
    For example, Amoxicillin's sales plummeted from 30 million yuan in a single quarter to several million yuan.
    In short, in terms of hospital sales and value, companies that originally won the bid with high prices have basically withdrawn from the public hospital market.
     
      Did the new so-called "spoilers" take advantage of it? Not necessarily, sales and prices are right there.
    The spoilers seem to "do not speak martial ethics", but in fact there is a lot of mystery behind them.
    After the second batch of national procurement, foreign-funded enterprises gradually withdrew from centralized procurement at all levels.
    Of course, they have their own considerations, such as the global market, such as brand influence, such as the participation of innovative drugs in national talks.
    Probably, under the current centralized procurement rules, there is something to do or not to do.
     
      On the other hand, domestic companies have finally had the opportunity to enter public hospitals, and naturally they have to seize the opportunity at all costs.
    The domestic industrial enterprises that participated in the centralized procurement and ultimately won, mainly include the following two categories:
     
      The first category is large-scale enterprises with super comprehensive strength.
    On research and development, a lot of new products are lining up.
    In terms of scale, a single factory with a large production capacity can guarantee national supply.
    In terms of cost control, if the production capacity goes up, the cost will naturally come down.
    On the extension of upstream and downstream industries, there are raw material and packaging material production companies in the upstream, and pharmaceutical companies and marketing teams in the downstream .
    When collecting quotations, the prices can naturally be explored to the end.
    Medicine Medicine Medicine
     
      Another type of enterprise has been in the circulation market for many years and does not involve the public hospital market.
    This type of company has been in the market for many years and has long been accustomed to price fighting, and cost control is its trick.
    The author has worked for many years in a company with circulation and pharmnet.
    com.
    cn/" target="_blank">investment promotion as its main sales model, and has seen many varieties that cost about 1 yuan per bottle (100 tablets).
    It is not that the quality of these products is unqualified, but that the cost control is done well.
    Large-scale purchase of raw materials, continuous batch feeding, piece-rate wages for workers, large-size inner and outer packaging.
    .
    .
    In short, within the scope of laws and regulations, the cost control is achieved to the extreme.
    pharmnet.
    com.
    cn/" target="_blank">Merchantspharmnet.
    com.
    cn/" target="_blank"> Merchants Merchants
     
      Which province does not have a large number of such industrial enterprises.
    In addition, they are also selecting varieties with sales advantages, actively making consistency evaluations, and participating in national procurement.
    Even if there is no R&D capability and the consistency evaluation is hindered, you can still participate in the provincial centralized procurement.
    This time, the collection of more than 30 varieties in Henan attracted nearly 300 manufacturers to participate, with the highest drop of 98%.
     
      Is the low-price bidding chicken ribs?
      Is the low-price bidding chicken ribs?
     
      Under the new normal of centralized procurement, instead of complaining about others, people in the industry should calm down and consider how to deal with it, because this is just the beginning.
     
      Centralized procurement has the advantages of centralized procurement.
    In the face of price competition, some companies withdraw from "group chat.
    " They have no way or can't find a better solution in a short time.
    It can be seen how important it is to take precautions and how helpless it is to boil frogs in warm water.
    Especially companies that rely on a few clinical varieties to dominate the world, because they have good sales and profits every year, the sense of crisis is not strong, and they are accustomed to lying down and winning, which leads to the deterioration of their limbs.
    Once centralized procurement came, the public hospital market that depended on for survival disappeared at once.
     
      Collect prices, there is no cost advantage.
    I quoted 1.
    2 yuan, but I couldn't produce it at 2.
    1 yuan, so I would pay for how much I produced.
    Let's fight for research and development.
    I haven't done it for so many years, and no new products will be released in the future.
    This is difficult to handle, and it is difficult for a clever woman to cook without rice.
    It may be a good choice to adjust sales channels, focus on controlled sales or commercial markets, and transform sales models.
    It's not too late to make up for it.
     
      Whether or not winning the bid at a low price for centralized procurement is a tasteless one depends on the strength of the enterprise and the pattern of the marketing trader.
    A certain manufacturer's indapamide tablets won the bid for centralized procurement in a large province in central China.
    The research organization concluded that the clinical market sales of indapamide tablets are small, and the volume and price have not changed much, but some product traders use the opportunity of provincial procurement to develop a series of market planning and marketing plans.
    There has been little change, but the sales volume of the province has increased by leaps and bounds from dozens of pieces in January to 3,000 pieces in a month.
    The market share has soared and the province's commercial sales network has been systematically established.
    This is called a borrowing.
     
      For the significance of centralized procurement, we cannot just look at the sales and profits of hospitals.
    Hospital clinical sales are the engine of pharmaceutical market sales.
    To seize the clinical market is equivalent to seizing the commanding heights of marketing.
    On the contrary, if you lose the hospital market, you may be able to survive a period of time due to medication compliance in a short period of time.
    In the long run, it is inevitable that market share will decrease, unless you want to voluntarily give up.
     
      Therefore, centralized harvesting is not chicken ribs, but very important.
    The key is to choose a high place and go to a wide place.
     
      Sales transformation to other channels
      Sales transformation to other channels
     
      What should the manufacturer do? The author offers three suggestions:
      What should the manufacturer do? The author offers three suggestions:
     
      1.
    Actively do consistency evaluation and participate in the national centralized procurement and provincial-level Group A competition.
    Although it is impossible to predict which varieties will be included in the collection at all levels, it is always good to take precautions.
    Forewarned is forearmed, without prejudging the waste.
     
      2.
    Control product costs and be prepared for price competition.
    Cost control is a manifestation of the comprehensive strength of industrial enterprises, involving all aspects of business operations, including production capacity, management, supply chain, marketing, equipment, technology, scale, and so on.
    The cost is well controlled.
    The high price of the winning election can increase profits, and the low price of the winning election can be invincible.
     
      3.
    Sales transformation, there is no way to go.
    An pharmnet.
    com.
    cn/agent_product/" target="_blank">agent tells the author, after Jicai, his loss of a variety of hospital sales of 1 million boxes a year in the province.
    However, the problem is not big, he has more varieties, not bright in the east and bright in the west.
    The same is true for the industry.
    Although the selection of varieties is not as flexible as the agents, the ship is easy to turn around, and the sales transformation can be done in time.
    Starting from other channels and terminals, the room for maneuver is not small.
    pharmnet.
    com.
    cn/agent_product/" target="_blank">Agentpharmnet.
    com.
    cn/agent_product/" target="_blank"> Agent Agent
     
      After all, manufacturers are "bookmakers" with varieties in their hands, and when agents face the huge competition for centralized procurement by the Medical Insurance Bureau, they have to withstand the adjustment of medical insurance catalogues, the increase in operating costs such as rent and labor, and the "two-invoice system" is combined.
    A series of severe tests such as increased regulatory risks, flat channels, and e-commerce impacts have not been small.
     
      For agents to break through, they must first make correct predictions on centralized procurement policies and varieties.
    Centralized procurement must be normalized, and biosimilar drugs and proprietary Chinese medicines will also be included.
    Agents must be predictable when choosing varieties: Don’t act as agents for the varieties that are about to be collected.
    Otherwise, after two or three years, the market will be hard to cultivate.
    When they encounter centralized sourcing, the manufacturer will withdraw the agency right.
    When looking for new drugs with clinical value, or varieties that have not been included in the scope of national centralized procurement.
    At the channel level, it is possible to expand out-of-hospital channels while retaining the advantages of clinical channels.
    After all, centralized procurement is mainly aimed at stock varieties and the hospital market, while the pharmaceutical industry has three major channels and six major terminals.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.